The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

• Status: RECRUITING
• Trial end date: 2029-08-10

Summary

A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of Pola-ZR2 (polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide) versus ZR2 (zanubrutinib, rituximab and lenalidomide) in the treatment of old patients with de novo diffuse large B-cell lymphoma

• Phase: PHASE3

Details

• Lead Sponsor: Ruijin Hospital
• Treatments: Lenalidomide; polatuzumab vedotin; Rituximab; zanubrutinib